Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Finasteride for benign prostatic hyperplasia.

S Hasinski1, J L Miller, L I Rose

  • 1Hahnemann University School of Medicine, Philadelphia, Pennsylvania.

American Family Physician
|November 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prenatal diagnosis of umbilical-portal-systemic venous shunt associated with gestational alloimmune liver disease.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2025
Same author

Resolution of selective fetal growth restriction after laser surgery for twin-to-twin transfusion syndrome can be predicted by predisease growth discordance.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2025
Same author

Standardized approach to ultrasound-guided balloon puncture for reversal of tracheal occlusion in congenital diaphragmatic hernia.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2024
Same author

MoMo pregnancies, Mo problems: monochorionic monoamniotic triplet pregnancy with conjoined twins.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2024
Same author

Lymphoma.

The Journal of comparative medicine and veterinary archives·2022
Same author

Patient-matched fetal simulator for fetoscopic myelomeningocele closure.

Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology·2022
Same journal

For Post-stent Patients With Atherosclerotic Coronary Vascular Disease Who Are Taking an Anticoagulant, Adding Aspirin Worsens Outcomes.

American family physician·2026
Same journal

Nausea and Vomiting During Pregnancy.

American family physician·2026
Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease: Diagnosis and Management.

American family physician·2026
Same journal

Aerobic Exercise Is the Better Exercise Modality for Knee Osteoarthritis.

American family physician·2026
Same journal

Overscreening Leads to Overdiagnosis of MASLD.

American family physician·2026
Same journal

Type 2 Diabetes: Outpatient Insulin Management.

American family physician·2026
See all related articles

Finasteride effectively reduces prostate volume and improves urine flow by inhibiting 5 alpha-reductase. This treatment for benign prostatic hyperplasia offers minimal side effects, with DHT levels returning to normal after discontinuation.

Area of Science:

  • Endocrinology
  • Urology
  • Pharmacology

Background:

  • Benign prostatic hyperplasia (BPH) pathogenesis involves 5 alpha-dihydrotestosterone (DHT), the active form of testosterone.
  • The enzyme 5 alpha-reductase catalyzes testosterone conversion to DHT within prostatic tissue.

Purpose of the Study:

  • To evaluate the efficacy and outcomes of Finasteride in managing benign prostatic hyperplasia.
  • To understand the mechanism of action and therapeutic duration of Finasteride.

Main Methods:

  • Competitive inhibition of 5 alpha-reductase by Finasteride.
  • Oral administration of Finasteride for BPH treatment.

Main Results:

  • Maximum reduction in prostatic volume observed after three months of oral Finasteride therapy.

Related Experiment Videos

  • Significant improvement in urine flow rates reported in most patients.
  • Minimal side effects associated with Finasteride treatment.
  • Serum DHT levels normalize within two weeks post-treatment discontinuation.

    • Conclusions:

    • Finasteride is an effective treatment for benign prostatic hyperplasia, targeting the DHT pathway.
    • The drug demonstrates a favorable safety profile and rapid reversibility of effects upon cessation.